Latest News for SalMar Stock (OTC:SALRY)

SalMar ASA produces and sells farmed salmon internationally. It operates hatcheries and controls the farming at all stages until the fish are ready to be harvested, processed, and packaged into various products. Products are developed with new mixes and packing methods to make it more convenient for customers. The salmon are sold through an in-house salesforce and through close partners of the company. Proximity to customers and tracking the use of resources plays a factor in delivering the raw material. Customers include importers, exporters, and larger processing companies and retail chains.

SalMar ASA

JP Morgan analyst Eric Joseph reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Overweight and maintains $25 price target.

News

Price Target

Reiteration

Analyst Ratings

TGTX

JP Morgan Reiterates Overweight on TG Therapeutics, Maintains $25 Price Target

Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) has outperformed the market over the past 5 years by 32.5% on an annualized basis producing an average annual return of 43.81%. Currently, Alpha Metallurgical has a market capitalization of $4.39 billion. 
Buying $1000 In AMR: If an investor had bought $1000 of AMR stock 5 years ago, it would be worth $5,995.03 today based on a price of $337.64 for AMR at the time of writing.
<h3>Alpha Metallurgical's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713461447_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Alpha Metallurgical 5 Years Ago Would Be Worth This Much Today

Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) has outperformed the market over the past 20 years by 4.65% on an annualized basis producing an average annual return of 12.31%. Currently, Nike has a market capitalization of $143.10 billion. 
Buying $100 In NKE: If an investor had bought $100 of NKE stock 20 years ago, it would be worth $1,031.44 today based on a price of $94.81 for NKE at the time of writing.
<h3>Nike's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713461442_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Nike 20 Years Ago Would Be Worth This Much Today

Stifel analyst J. Bruce Chan maintains Werner Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WERN#NASDAQ">WERN</a>) with a Hold and lowers the price target from $42 to $39.

WERN

Stifel Maintains Hold on Werner Enterprises, Lowers Price Target to $39

Live On CNBC, Alaska Airlines CEO Ben Minicucci Says Encouraged With The Quality Plan Boeing Is Putting In Place; Hopeful That Hawaiian Air Merger Would Be Completed Sometime Later This Year

Stifel analyst Tore Svanberg maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and raises the price target from $31 to $36.

SMTC

Stifel Maintains Buy on Semtech, Raises Price Target to $36

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Iran Foreign Minister Tells UN Security Council That Iran's Defense And Countermeasures Have Concluded And Israel 'Must Be Compelled To Stop Any Further Military Adventurism Against Our Interests'

Windtree Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares are trading lower by 20% to $0.32 during Thursday&#8217;s session after the company announced it approved a 1-for-18 reverse stock split of its <a href="https://www.benzinga.com/pressreleases/24/04/g38311510/windtree-therapeutics-announces-reverse-stock-split">common stock</a>. 
This measure, effective April 19, 2024, aims to increase the market price per share, ensuring compliance with Nasdaq&#8217;s minimum bid price requirement. Each 18 shares will be converted into 1 share without altering the stock&#8217;s par value. 
The split affects all shareholders proportionally and does not change their ownership percentage, with fractional shares rounded up.
See Also: <a href="https://www.benzinga.com/news/earnings/24/04/38314454/netflix-stock-is-in-the-spotlight-thursday-whats-going-on">Netflix Stock Is In The Spotlight Thursday: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">Should I Sell My WINT Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Windtree Therapeutics have lost 87.55% year to date. This compares to the average annual return of -84.5%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Windtree Therapeutics stock currently has an RSI of 50.46, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WINT has a 52-week high of and a 52-week low of

WINT

Why Windtree Therapeutics (WINT) Stock Is Getting Hammered

Stifel analyst Tore Svanberg maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Hold and lowers the price target from $82 to $72.

Stifel Maintains Hold on ON Semiconductor, Lowers Price Target to $72

Ladenburg Thalmann analyst Matthew Kaplan reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Buy and maintains $39 price target.

Ladenburg Thalmann Reiterates Buy on TG Therapeutics, Maintains $39 Price Target

Stifel analyst Tore Svanberg maintains MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Buy and raises the price target from $105 to $115.

MTSI

Stifel Maintains Buy on MACOM Technology Solns, Raises Price Target to $115

Stifel analyst Tore Svanberg maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and raises the price target from $94 to $98.

MCHP

Stifel Maintains Buy on Microchip Technology, Raises Price Target to $98

Stifel analyst Tore Svanberg maintains Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Sell and lowers the price target from $23 to $21.

AOSL

Stifel Maintains Sell on Alpha & Omega, Lowers Price Target to $21

WIIM

Windtree Therapeutics shares are trading lower after the company approved a 1-for-18 reverse stock split.

Stifel analyst Jonathan Block maintains Align Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) with a Buy and raises the price target from $350 to $400.

ALGN

Stifel Maintains Buy on Align Tech, Raises Price Target to $400

Zoom Video Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is holding its ground in the <a href="https://www.benzinga.com/news/24/02/37343923/zoom-tops-estimates-as-it-pledges-to-democratize-ai-access">AI wave, despite intense competition</a>.
The company has refused its channel strategy, which is generating "positive partner feedback," according to Rosenblatt Securities.
The Zoom Video Communications Analyst: Catharine Trebnick upgraded the rating for Zoom Video Communications from Neutral to Buy, while keeping the price target unchanged at $75.
The Zoom Video Communications Thesis: The partnerships with Avaya and Amazon.com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) AWS could drive incremental revenue, Trebnick said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The company's product momentum remains strong, with Zoom Phone boasting of 95 customers with over 10,000 seats, which represents 27% year-on-year growth, while "CCaaS has tripled in adoption with larger average deal sizes," and more than 510,000 accounts now use Zoom AI Companion, the analyst stated.
"Recent channel checks (late March) confirm the sustained success of Zoom Phone and an encouraging uptick in CCaaS activity," she added.
"Zoom&#8217;s emphasis on AI-powered advancements positions the company well to address the growing demand for intelligent and productive collaboration tools," Trebnick further wrote. 
ZM Price Action: Shares of Zoom Video Communications were up 1.6% to $60.04 at the time of publication on Thursday.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38319509/treasury-yields-head-to-danger-zone-analyst-forecasts-potential-spike-to-5-disorder">Treasury Yields Head To &#8216;Danger Zone&#8217;: Analyst Forecasts Potential Spike To 5%, Disorderly Sell-Off For Markets</a>
Photo: Shutterstock

Analyst Color

Upgrades

Tech

AMZN

Zoom Leverages 'AI-Powered Advancements' For Growth: Analyst Sees Market Edge

B. Riley Securities analyst Christopher Souther maintains Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) with a Buy and lowers the price target from $18 to $15.

BEEM

B. Riley Securities Maintains Buy on Beam Glb, Lowers Price Target to $15

JMP Securities analyst Jonathan Wolleben reiterates Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Market Outperform and maintains $8 price target.

RLYB

JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target

Lithium Americas Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAC#NYSE">LAC</a>) shares are trading lower Thursday after the company priced a <a href="https://www.benzinga.com/news/earnings/24/04/38315588/dow-surges-over-100-points-d-r-horton-posts-upbeat-earnings">$275 million public offering.</a>
The Details:
Lithium Americas <a href="https://www.benzinga.com/pressreleases/24/04/g38307058/lithium-americas-prices-us-275-million-underwritten-public-offering">announced the offering</a> of 55,000,000 of its common shares at a price to the public of $5.00 per share for aggregate gross proceeds to the company of $275 million.&nbsp;
The company intends to use the net proceeds to advance the construction and development of its Thacker Pass lithium project in Humboldt County, Nevada. The offering is expected to close on April 22 and is subject to customary closing conditions.&nbsp;
Related News: <a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock">What&#8217;s Going On With Arm Holdings Stock?</a>
<h2 class="wp-block-heading">Will LAC Stock Go Up?</h2>
When trying to assess whether or not Lithium Americas will trade higher from current levels, it's a good idea to take a look at analyst forecasts. 
Wall Street analysts have an average 12-month price target of $7.25 on Lithium Americas. The Street high target is currently at $9 and the Street low target is $5.50. Of all the analysts covering Lithium Americas, one has positive ratings, one has neutral ratings and no one has negative ratings.
In the last month, no analysts have adjusted price targets. Here's a look at recent price target changes <a href='https://www.benzinga.com/quote/LAC/analyst-ratings'>[Analyst Ratings]</a>. Benzinga also tracks Wall Street's most accurate analysts. Check out how analysts covering Lithium Americas have performed in recent history. 
Stocks don't move in a straight line. The average stock market return is approximately 10% per year. Lithium Americas is 52.08% down year-to-date. The average analyst price target suggests the stock could have further upside ahead.
For a broad overview of everything you need to know about Lithium Americas, visit <a href='https://www.benzinga.com/quote/LAC'>here</a>. If you want to go above and beyond, there's no better tool to help you do just that than <a href='https://pro.benzinga.com/'>Benzinga Pro</a>. Start your free trial today.
LAC Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Lithium Americas shares are down 27.3% at $4.81 at the time of publication Thursday.
Image: Csaba Nagy from Pixabay

Movers

Why Lithium Americas Stock Is Sinking

JMP Securities analyst Trevor Cranston reiterates Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) with a Market Outperform and maintains $11 price target.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for SalMar Stock (OTC:SALRY)

Tuesday, March 24, 2020